Claims
- 1. A compound of the formula (I): ##STR74## or a pharmaceutically accetpable salt thereof wherein one of A.sub.1 or A.sub.2 is a group of the formula (II) ##STR75## and R.sub.1, R.sub.2 and the one of A.sub.1, or A.sub.2 which is not a group of the formula (II) are the same or different and each is hydrogen, lower alkyl, lower alkoxy, lower alkenyl or lower alkynyl; provided that at least one of R.sub.1, R.sub.2, A.sub.1 and A.sub.2 is hydrogen, E is oxygen; G is nitro or cyano; X is methylene; and Q is alkylene of 1 to 8 carbon atoms. 1 methylene group within the group Q, other than a methylene covalently bound to an ether oxygen, being unsubstituted or substituted by hydroxyl, and R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are each hydrogen, halogen, nitro, hydroxy, cyano, carboxyl, amino, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkoxy carbonyl, lower alkanoyl, lower alkanoyloxy, mono- or di-lower alkyl amino, mono-or di-lower alkanoyl amino, phenyl, lower alkylphenyl, phenoxycarbonyl, or benzyloxycarbonyl.
- 2. A compound according to claim 1 wherein R.sub.1, R.sub.2 and A.sub.1 are the same or different and each is hydrogen or lower alkyl, and A.sub.2 is a substituent of the formula (II).
- 3. A compound according to claim 2 wherein one of R.sub.3 to R.sub.7 is hydrogen.
- 4. A compound according to claim 2 wherein two of R.sub.3 to R.sub.7 are hydrogen.
- 5. A compound according to claim 4 wherein R.sub.3 is hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy, lower alkoxycarbonyl, phenyl, cyano, carboxyl, halogen, nitro, amino, mono- or di-lower alkyl amino, or mono- or di-lower alkanoyl amino, R.sub.4 is hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy or lower alkoxy carbonyl, and R.sub.5 is hydrogen or lower alkyl; and R.sub.6 and R.sub.7 are both hydrogen.
- 6. A compound according to claim 1 wherein R.sub.3 is lower alkyl and R.sub.4 to R.sub.7 are all hydrogen.
- 7. A compound according to claim 6 wherein R.sub.3 is methyl, ethyl or n-propyl.
- 8. A compound according to claim 7 wherein R.sub.3 is n-propyl at position 2' of the phenyl ring of substituent (II).
- 9. A compound according to claim 1 wherein R.sub.3 is fluorine and R.sub.4 to R.sub.7 are all hydrogen.
- 10. A compound according to claim 9 wherein R.sub.3 is fluorine at 4' at the phenyl ring of substituent (II).
- 11. A compound according to claim 1 wherein R.sub.3 is fluorine, R.sub.4 is lower alkyl, and R.sub.5 to R.sub.7 are all hydrogen.
- 12. A compound according to claim 11 wherein R.sub.4 is n-propyl.
- 13. A compound according to claim 12 wherein R.sub.3 is at position 4' and R.sub.4 is at position 2' of the phenyl ring of substituent (II).
- 14. A compound according to claim 5 wherein R.sub.3 is lower alkanoyl, R.sub.4 is hydroxy, R.sub.5 is lower alkyl, R.sub.6 and R.sub.7 are hydrogen.
- 15. A compound according to claim 14 wherein R.sub.3 is at position 3', R.sub.4 is at position 4' and R.sub.5 is at position 2' of the phenyl ring of substituent (II).
- 16. A compound according to claim 15 wherein R.sub.3 is acetyl and R.sub.5 is n-propyl.
- 17. A compound according to claim 1 wherein R.sub.1 and R.sub.2 and the one of A.sub.1 and A.sub.2 which is not a substituent of formula (II) are each hydrogen.
- 18. A compound according to claim 17 wherein R.sub.3 to R.sub.7 are all hydrogen.
- 19. A compound according to claim 1 wherein Q represents ethylene.
- 20. A compound according to claim 1 wherein Q represents ethylene, propylene, butylene or pentylene.
- 21. A compound according to claim 20 where one methylene group other than a methylene bound to an ether oxygen is substituted with hydroxyl.
- 22. A compound according to claim 1 wherein Q is methylene or ethylene.
- 23. A compound according to claim 1 wherein Q is propylene, butylene, pentylene or hexylene.
- 24. A compound according to claim 1 wherein Q is propylene substituted by hydroxyl, butylene substituted by hydroxyl, pentylene substituted by hydroxyl or hexylene substituted by hydroxyl.
- 25. A compound according to claim 1 wherein Q is 2-hydroxypropylene.
- 26. A compound according to claim 1 wherein G is cyano.
- 27. A compound according to claim 1 wherein G is nitro.
- 28. A compound according to claim 27 selected from the group consisting of:
- 4-hydroxy-3-nitro-7-(2-phenylethoxy)coumarin
- 7-[2-n-propyl-4-fluorophenyl]-ethoxy-4-hydroxy-3-nitrocoumarin and the pharmaceutically acceptable salts thereof.
- 29. A compound according to claim 28 selected from the group consisting of:
- 3-cyano-4-hydroxyphenylethoxycoumarin,
- 3-cyano-4-hydroxy-7-(2-phenylethoxy) coumarin,
- 3-cyano-4-hydroxy-7-(3-phenylpropoxy)coumarin,
- 3-cyano-4-hydroxy-7-(4-phenylbutoxy coumarin,
- 3-cyano-4-hydroxy-7-(5-phenylpentoxy) coumarin,
- 5-(3-[4-acetyl-3-hydroxy-2-n-propylphenyl]butoxy-3-cyano-4-hydroxycoumarin
- and pharmaceutically acceptable salts thereof.
- 30. A pharmaceutical composition useful for the inhibition in humans of the release of mediators of allergic response and for the inhibition in humans of the action of said mediators which comprises an effective amount of a compound of the formula (I): ##STR76## or a pharmaceutically acceptable salt thereof wherein one of A.sub.1 or A.sub.2 is a group of the formula (II): ##STR77## and R.sub.1, R.sub.2 and the one of A.sub.1 or A.sub.2 which is not a group of the formula (II) are the same or different and each is hydrogen, lower alkyl, lower alkoxy, lower alkenyl or lower alkynyl; provided that at least one of R.sub.1, R.sub.2, A.sub.1 and A.sub.2 is hydrogen, E is oxygen; G is nitro or cyano; X is methylene; and Q is alkylene of 1 to 8 carbon atoms, 1 methylene group within the group Q, other than a methylene covalently bound to an ether oxygen, being unsubstituted or substituted by hydroxyl, and R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are each hydrogen, halogen, nitro, hydroxy, cyano, carboxyl, amino, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkoxy carbonyl, lower alkanoyl, lower alkanoyloxy, mono- or di-lower alkyl amino, mono- or di-lower alkanoyl amino, phenyl, lower alkylphenyl, phenoxycarbonyl, or benzyloxycarbonyl in combination with a pharmaceutically acceptable carrier.
- 31. A composition according to claim 30 wherein R.sub.1, R.sub.2 and A.sub.1 are the same or different and each is hydrogen or lower alkyl, and A.sub.2 is a substituent of the formula (II).
- 32. A composition according to claim 31 wherein one of R.sub.3 to R.sub.7 is hydrogen.
- 33. A composition according to claim 31 wherein two of R.sub.3 to R.sub.7 are hydrogen.
- 34. A composition according to claim 33 wherein R.sub.3 is hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy, lower alkoxycarbonyl, phenyl, cyano, carboxyl, halogen, nitro, amino, mono- or di-lower alkyl amino, or mono- or di-lower alkanoyl amino, R.sub.4 is hydrogen, loweralkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy or lower alkoxy carbonyl, and R.sub.5 is hydrogen or lower alkyl; and R.sub.6 and R.sub.7 are both hydrogen.
- 35. A composition according to claim 30 wherein R.sub.3 is lower alkyl and R.sub.4 to R.sub.7 are all hydrogen.
- 36. A composition according to claim 35 wherein R.sub.3 is methyl, ethyl or n-propyl.
- 37. A composition according to claim 36 wherein R.sub.3 is n-propyl at position 2' of the phenyl ring of substituent (II).
- 38. A composition according to claim 30 wherein R.sub.3 is fluorine and R.sub.4 to R.sub.7 are all hydrogen.
- 39. A composition according to claim 38 wherein R.sub.3 is flourine at 4' at the phenyl ring of substituent (11).
- 40. A composition according to claim 30 wherein R.sub.3 is fluorine, R.sub.4 is lower alkyl, and R.sub.5 to R.sub.7 are all hydrogen.
- 41. A composition according to claim 40 wherein R.sub.4 is n-propyl.
- 42. A composition according to claim 41 wherein R.sub.3 is at position 4' and R.sub.4 is at position 2' of the phenyl ring of substituent (II).
- 43. A composition according to claim 33 wherein R.sub.3 is lower alkanoyl, R.sub.4 is hydroxy, R.sub.5 is lower alkyl, R.sub.6 and R.sub.7 are hydrogen.
- 44. A composition according to claim 43 wherein R.sub.3 is at position 3', R.sub.4 is at position 4' and R.sub.5 is at position 2' of the phenyl ring of substituent (II).
- 45. A composition according to claim 44 wherein R.sub.3 is acetyl and R.sub.5 is n-propyl.
- 46. A composition according to claim 30 wherein R.sub.1 and R.sub.2 and the one of A.sub.1 and A.sub.2 which is not a substituent of formula (II) all are each hydrogen.
- 47. A composition according to claim 46 wherein R.sub.3 to R.sub.7 are all hydrogen.
- 48. A composition according to claim 30 wherein Q represents ethylene.
- 49. A composition according to claim 30 wherein Q represents ethylene, propylene, butylene or pentylene.
- 50. A composition according to claim 49 where one methylene group other than a methylene bound to an ether oxygen is substituted with hydroxyl.
- 51. A composition according to claim 30 wherein Q is methylene or ethylene.
- 52. A composition according to claim 30 wherein Q is propylene, butylene, pentylene or hexylene.
- 53. A composition according to claim 52 wherein Q is propylene substituted by hydroxyl, butylene substituted by hydroxyl, pentylene substituted by hydroxyl or hexylene substituted by hydroxyl.
- 54. A composition according to claim 53 wherein Q is 2-hydroxypropylene.
- 55. A composition according to claim 30 wherein G is cyano.
- 56. A composition according to claim 30 wherein G is nitro.
- 57. A composition according to claim 56 comprising a compound selected from the group consisting of:
- 4-hydroxy-3-nitro-7-(2-phenylethoxy)coumarin
- 7-[2-n-propyl-4-fluorophenyl]-ethoxy-4-hydroxy-3-nitrocoumarin and the pharmaceutically acceptable salts thereof.
- 58. A composition according to claim 30 in the form of a microfine powder suitable for administration by insufflation.
- 59. A composition according to claim 30 in a form suitable for administration by injection.
- 60. A composition according to claim 30 in the form of an ointment cream or lotion for topical application.
- 61. A composition according to claim 30 in a form suitable for oral administration.
- 62. A method of inhibiting mediators of allergic response in humans and for inhibiting in humans the action of said mediators which comprises administering to a human in need thereof an effective amount of a compound of the formula (I): ##STR78## or a pharmaceutically acceptable salt thereof wherein one of A.sub.1 A.sub.2 is a group of the formula (II): ##STR79## and R.sub.1, R.sub.2 and the one of A.sub.1 or A.sub.2 which is not a group of the formula (II) are the same or different and each is hydrogen, lower alkyl, lower alkoxy, lower alkenyl or lower alkynyl; provided that at least one of R.sub.1, R.sub.2, A.sub.1 and A.sub.2 is hydrogen, E is oxygen; G is nitro or cyano; X is methylene; and Q is alkylene of 1 to 8 carbon atoms, 1 methylene group within the group Q, other than a methylene covalently bound to an ether oxygen, being unsubstituted or substituted by hydroxyl, and R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are each hydrogen, halogen, nitro, hydroxy, cyano, carboxyl, amino, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkoxy carbonyl, lower alkanoyl, lower alkanoyloxy, mono- or di-lower alkyl amino, mono- or di-lower alkanoyl amino, phenyl, lower alkylphenyl, phenoxycarbonyl, or benzyloxycarbonyl, in combination with a pharmaceutically acceptable carrier.
- 63. A method according to claim 62 wherein R.sub.1, R.sub.2 and A.sub.1 are the same or different and each is hydrogen or lower alkyl, and A.sub.2 is a substituent of the formula (II).
- 64. A method according to claim 63 wherein one of R.sub.3 to R.sub.7 is hydrogen.
- 65. A method according to claim 63 wherein two of R.sub.3 to R.sub.7 are hydrogen.
- 66. A method according to claim 65 wherein R.sub.3 is hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy, lower alkoxycarbonyl, phenyl, cyano, carboxyl, halogen, nitro amino, mono- or di-lower alkyl amino, or mono- or di-lower alkanoyl amino, R.sub.4 is hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy or lower alkoxy carbonyl, and R.sub.5 is hydrogen or lower alkyl; and R.sub.6 and R.sub.7 are both hydrogen.
- 67. A method according to claim 62 wherein R.sub.3 is lower alkyl and R.sub.4 to R.sub.7 are all hydrogen.
- 68. A method according to claim 67 wherein R.sub.3 is methyl, ethyl or n-propyl.
- 69. A method according to claim 68 wherein R.sub.3 is n-propyl at position 2' of the phenyl ring of substituent (II).
- 70. A method according to claim 62 wherein R.sub.3 is fluorine and R.sub.4 to R.sub.7 are all hydrogen.
- 71. A method according to claim 70 wherein R.sub.3 is fluorine at 4' at the phenyl ring of substituent (II).
- 72. A method according to claim 62 wherein R.sub.3 is fluorine, R.sub.4 is lower alkyl, and R.sub.5 to R.sub.7 are all hydrogen.
- 73. A method according to claim 72 wherein R.sub.4 is n-propyl.
- 74. A method according to claim 73 wherein R.sub.3 is at position 4' and R.sub.4 is at position 2' of the phenyl ring of substituent (II).
- 75. A method according to claim 65 wherein R.sub.3 is lower alkanoyl, R.sub.4 is hydroxy, R.sub.5 is lower alkyl, R.sub.6 and R.sub.7 are hydrogen.
- 76. A method according to claim 75 wherein R.sub.3 is at position 3', R.sub.4 is at position 4' and R.sub.5 is at position 2' of the phenyl ring of substituent (II).
- 77. A method according to claim 76 wherein R.sub.3 is acetyl and R.sub.5 is n-propyl.
- 78. A method according to claim 62 wherein R.sub.1 and R.sub.2 and the one of A.sub.1 and A.sub.2 which is not a substituent of formula (II) are each hydrogen.
- 79. A method according to claim 78 wherein R.sub.3 to R.sub.7 are all hydrogen.
- 80. A method according to claim 62 wherein Q represents ethylene.
- 81. A method according to claim 62 wherein Q represents ethylene, propylene, butylene or pentylene.
- 82. A method according to claim 81 where one methylene group other than a methylene bound to an ether oxygen is substituted with hydroxyl.
- 83. A method according to claim 62 wherein Q is methylene or ethylene.
- 84. A method according to claim 63 wherein Q is propylene, butylene, pentylene or hexylene.
- 85. A method according to claim 84 wherein Q is propylene substituted by hydroxyl, butylene substituted by hydroxyl, pentylene substituted by hydroxyl or hexylene substituted by hydroxyl.
- 86. A method according to claim 85 wherein Q is 2-hydroxypropylene.
- 87. A method according to claim 62 wherein G is cyano.
- 88. A method according to claim 62 wherein G is nitro.
- 89. A method according to claim 62 which comprises administering a compound from the group comprising of:
- 3-cyano-4-hydroxyphenylethoxycoumarin,
- 3-cyano-4-hydroxy-7-(2-phenylethoxy) coumarin,
- 3-cyano-4-hydroxy-7-(3-phenylpropoxy)coumarin,
- 3-cyano-4-hydroxy-7-(4-phenylbutoxy) coumarin,
- 3-cyano-4-hydroxy-7-(5-phenylpentoxy) coumarin,
- 5-(3-[4-acetyl-3-hydroxy-2-n-propylphenyl]butoxy-3-cyano-4-hydroxycoumarin
- and pharmaceutically acceptable salts thereof.
- 90. A method according to claim 62 wherein the administration is by insufflation.
- 91. A method according to claim 62 wherein administration is by injection.
- 92. A method according to claim 62 wherein administration is topical.
- 93. A method according to claim 62 wherein administration is oral.
Priority Claims (6)
Number |
Date |
Country |
Kind |
39041/75 |
Sep 1975 |
GBX |
|
39042/75 |
Sep 1975 |
GBX |
|
4321/76 |
Feb 1976 |
GBX |
|
21276/76 |
May 1976 |
GBX |
|
21277/76 |
May 1976 |
GBX |
|
24450/76 |
Jun 1976 |
GBX |
|
Parent Case Info
This is a divisional of our copending application Ser. No. 780,246 filed Mar. 22, 1977 issued Jan. 23, 1979 now U.S. Pat. No. 4,136,192, which is a Continuation-in-part of U.S. Ser. No. 722,868 Sept, 13, 1976, now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
3567832 |
Boschetti et al. |
Mar 1971 |
|
3974289 |
Buckle et al. |
Aug 1976 |
|
4012407 |
Doyle et al. |
Mar 1977 |
|
4032544 |
Doyle et al. |
Jun 1977 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
780246 |
Mar 1977 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
722868 |
Sep 1976 |
|